- Q1 2024 Vir Biotechnology Inc Earnings Call TranscriptMay 02, 2024$9.18 (+5.03%)Earnings
- Q4 2023 Vir Biotechnology Inc Earnings Call TranscriptFeb 22, 2024$10.3 (+1.88%)Earnings
- Vir Biotechnology Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Vir Biotechnology Inc AASLD Late Breaking Data Update Call TranscriptNov 13, 2023
- Q3 2023 Vir Biotechnology Inc Earnings Call TranscriptNov 02, 2023$8.19 (+5.13%)Earnings
- Vir Biotechnology Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) TranscriptOct 25, 2023
- Vir Biotechnology Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Q2 2023 Vir Biotechnology Inc Earnings Call TranscriptAug 03, 2023$13.97 (-0.50%)Earnings
- Vir Biotechnology Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Vir Biotechnology Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Vir Biotechnology Inc at Needham Healthcare Conference (Virtual) TranscriptApr 18, 2023
- Vir Biotechnology Inc at Barclays Global Healthcare Conference TranscriptMar 15, 2023
- Vir Biotechnology, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 09:45 AM TranscriptJan 10, 2023
- Vir Biotechnology Inc at H C Wainwright NASH Investor Conference (Virtual) TranscriptOct 18, 2022
- Vir Biotechnology Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- Vir Biotechnology Inc at Needham Healthcare Conference (Virtual) TranscriptApr 11, 2022
- Vir Biotechnology Inc Corporate Call on Sotrovimab's Retained Activity Against the Omicron SARS-CoV-2 Variant TranscriptDec 07, 2021
- Vir Biotechnology Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
Q2 2023 Vir Biotechnology Inc Earnings Call Transcript
Hello, welcome to Vir Biotechnology Second Quarter 2023 Financial Results and Business Update Call. (Operator Instructions) As a reminder, this conference call is being recorded. (Operator Instructions)
I will now turn the call over to Sasha Damouni Ellis, Executive Vice President, Chief Corporate Affairs Officer. You may begin, Ms. Damouni Ellis.
Thank you, and good afternoon. With me today are Marianne De Backer, Chief Executive Officer; Dr. Phil Pang, Chief Medical Officer; and Sung Lee, Chief Financial Officer. Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. These risks and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)